2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2985

Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Abstract Number: 2378

Mycophenolate Mofetil As a Steroid Sparing Agent in Polymyositis and Dermatomyositis: a Systematic Review of the Literature
Abstract Number: 724

Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
Abstract Number: 1790

Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Abstract Number: 1886

Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients
Abstract Number: 1817

Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain
Abstract Number: 288

Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Abstract Number: 2368

Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Abstract Number: 1909

Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns
Abstract Number: 308

Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis
Abstract Number: 969

Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
Abstract Number: 3082

Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Abstract Number: 854

Nationwide Incidence of Anti Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis in Iceland
Abstract Number: 1083

Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Abstract Number: 846

Nationwide Trends in in-Hospital Mortality and Hospitalization Associated with Systemic Sclerosis (SSc)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].